Lecap Asset Management Ltd. Invests $833,000 in Jazz Pharmaceuticals PLC $JAZZ

Lecap Asset Management Ltd. bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 3rd quarter, Holdings Channel reports. The fund bought 6,319 shares of the specialty pharmaceutical company’s stock, valued at approximately $833,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JAZZ. Philip James Wealth Mangement LLC grew its stake in Jazz Pharmaceuticals by 42.0% in the second quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after purchasing an additional 4,675 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in Jazz Pharmaceuticals by 75.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock worth $6,147,000 after buying an additional 24,850 shares during the last quarter. Inspire Investing LLC acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $689,000. Baird Financial Group Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $539,000. Finally, Kennedy Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $1,100,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JAZZ. Robert W. Baird lifted their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Wells Fargo & Company boosted their price objective on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Bank of America increased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Finally, Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $201.80.

Jazz Pharmaceuticals Stock Down 5.4%

JAZZ stock opened at $160.25 on Friday. The stock has a market cap of $9.74 billion, a PE ratio of -26.40, a price-to-earnings-growth ratio of 0.79 and a beta of 0.27. The firm’s 50-day simple moving average is $163.37 and its 200 day simple moving average is $137.06. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 5,500 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total transaction of $994,730.00. Following the completion of the transaction, the director owned 8,893 shares in the company, valued at approximately $1,608,387.98. The trade was a 38.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Robert Iannone sold 7,159 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $168.26, for a total value of $1,204,573.34. Following the transaction, the executive vice president directly owned 72,628 shares in the company, valued at $12,220,387.28. This trade represents a 8.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 123,791 shares of company stock valued at $21,991,850. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.